Literature DB >> 2525099

Neonatal induction of allogeneic tolerance prevents T cell-mediated autoimmunity in NOD mice.

A Bendelac1, C Boitard, J F Bach, C Carnaud.   

Abstract

Diabetes in the NOD mouse strain is a genetically programmed T cell-mediated autoimmune process that is directed against an as yet unknown antigen target(s) on pancreatic beta cells. To investigate whether the course of the autoimmune disease could be altered by immune manipulations of the T cell repertoire, we have induced allogeneic tolerance by injecting F1 semiallogeneic spleen cells into NOD neonates. This procedure resulted in a significant protection against both insulitis and diabetes. However, although it requires the induction of tolerance, as shown by the failure of non-tolerizing irradiated cells to prevent autoimmunity, protection appeared to be independent of the major histocompatibility complex haplotypes of the F1 spleen cells injected at birth, e.g. (C57BL/6 x NOD)F1, (CBA/Ca x NOD)F1 or (BALB/c x NOD)F1 cells. In addition, a similar degree of protection was induced, whether the tolerant state, as assessed by mixed lymphocyte reaction studies in vitro, was of short duration, approximately 6 weeks, or lasted for more than 12 weeks. Putative veto or suppressor functions of chimeric T cells were ruled out, since mice tolerized with T cell-depleted F1 spleen cells were equally protected. We conclude that the expression of spontaneous T cell-mediated autoimmunity can be modulated by immune manipulations at birth. Whether the protection observed in the present experiments resulted from the production of one or several specific holes in the autoimmune T cell repertoire, i.e. cross-tolerance, or whether it resulted from nonspecific disturbances of the emerging T cell repertoire remains to be elucidated.

Entities:  

Mesh:

Year:  1989        PMID: 2525099     DOI: 10.1002/eji.1830190406

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

1.  Excess of maternal HLA-DR3 antigens in HLA DR3,4 positive type 1 (insulin-dependent) diabetic patients.

Authors:  I Deschamps; J Hors; F Clerget-Darpoux; E Gardais; J J Robert; A Marcelli-Berge; H Lestradet; J Dausset
Journal:  Diabetologia       Date:  1990-07       Impact factor: 10.122

2.  Abnormal T cell selection on nod thymic epithelium is sufficient to induce autoimmune manifestations in C57BL/6 athymic nude mice.

Authors:  V Thomas-Vaslin; D Damotte; M Coltey; N M Le Douarin; A Coutinho; J Salaün
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

3.  Failure of a protective major histocompatibility complex class II molecule to delete autoreactive T cells in autoimmune diabetes.

Authors:  R M Slattery; J F Miller; W R Heath; B Charlton
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-15       Impact factor: 11.205

4.  Grafts of supplementary thymuses injected with allogeneic pancreatic islets protect nonobese diabetic mice against diabetes.

Authors:  J Salaün; N Simmenauer; P Belo; A Coutinho; N M Le Douarin
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-15       Impact factor: 11.205

5.  alpha/beta-T cell receptor (TCR)+CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10.

Authors:  K J Hammond; L D Poulton; L J Palmisano; P A Silveira; D I Godfrey; A G Baxter
Journal:  J Exp Med       Date:  1998-04-06       Impact factor: 14.307

Review 6.  Immunotherapy of type 1 diabetes: lessons for other autoimmune diseases.

Authors:  Jean-François Bach
Journal:  Arthritis Res       Date:  2002-05-09

7.  Overexpression of natural killer T cells protects Valpha14- Jalpha281 transgenic nonobese diabetic mice against diabetes.

Authors:  A Lehuen; O Lantz; L Beaudoin; V Laloux; C Carnaud; A Bendelac; J F Bach; R C Monteiro
Journal:  J Exp Med       Date:  1998-11-16       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.